- Home
- DHC vs CRGX Comparison
DHC vs CRGX Comparison
Compare DHC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHC
- CRGX
- Stock Information
- Founded
- DHC 1998
- CRGX 2021
- Country
- DHC United States
- CRGX United States
- Employees
- DHC N/A
- CRGX N/A
- Industry
- DHC Real Estate Investment Trusts
- CRGX
- Sector
- DHC Real Estate
- CRGX
- Exchange
- DHC Nasdaq
- CRGX Nasdaq
- Market Cap
- DHC 757.5M
- CRGX 190.0M
- IPO Year
- DHC N/A
- CRGX 2023
- Fundamental
- Price
- DHC $3.87
- CRGX $4.59
- Analyst Decision
- DHC Hold
- CRGX Hold
- Analyst Count
- DHC 3
- CRGX 7
- Target Price
- DHC $4.50
- CRGX $5.33
- AVG Volume (30 Days)
- DHC 1.1M
- CRGX 1.9M
- Earning Date
- DHC 08-04-2025
- CRGX 08-11-2025
- Dividend Yield
- DHC 1.08%
- CRGX N/A
- EPS Growth
- DHC N/A
- CRGX N/A
- EPS
- DHC N/A
- CRGX N/A
- Revenue
- DHC $1,511,515,000.00
- CRGX N/A
- Revenue This Year
- DHC $3.98
- CRGX $57.81
- Revenue Next Year
- DHC $4.50
- CRGX N/A
- P/E Ratio
- DHC N/A
- CRGX N/A
- Revenue Growth
- DHC 5.33
- CRGX N/A
- 52 Week Low
- DHC $2.00
- CRGX $3.00
- 52 Week High
- DHC $4.24
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- DHC 59.98
- CRGX 61.56
- Support Level
- DHC $3.50
- CRGX $4.32
- Resistance Level
- DHC $3.83
- CRGX $4.63
- Average True Range (ATR)
- DHC 0.16
- CRGX 0.16
- MACD
- DHC -0.02
- CRGX 0.04
- Stochastic Oscillator
- DHC 64.71
- CRGX 76.44
About DHC Diversified Healthcare Trust of Beneficial Interest
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.